Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Redox Intelligence in Hypoxic Tumor Microenvironments
2026-09-01
Hypoxia and nutrient competition reshape tumor and immune-cell metabolism, but the resulting redox phenotype is often under-measured. This thought-leadership guide shows how paired GSH and GSSG measurements can strengthen mechanism-focused studies, improve experimental decisions, and support more disciplined translational biomarker development.
-
Chemotherapy and Neoantigen Presentation in T Cell Therapy
2026-08-31
Sagie et al. identify the KRAS.G12V-specific TCR T104 and show that lymphodepleting chemotherapy enhances neoantigen-directed tumor killing by increasing immunoproteasome activity, HLA-I expression, and peptide presentation. The study provides a mechanistic framework for interpreting chemotherapy as an active modifier of tumor immune visibility rather than only as a conditioning treatment.
-
Reversine (A3760): Aurora Kinase Workflow Guide
2026-08-31
Reversine is an Aurora kinase inhibitor for controlled investigation of mitotic regulation, cell-cycle disruption, cancer cell proliferation inhibition, and apoptosis-related phenotypes. This guide explains how to prepare and quality-check the compound while distinguishing product-dossier potency values from workflow recommendations; it is not a clinical-use or disease-treatment protocol.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-30
Masitinib (AB1010), SKU A2942, provides a DMSO-compatible tool for studying KIT, PDGFRα, and PDGFRβ inhibition in cancer, mast-cell, and inflammatory research. It is unsuitable for aqueous or ethanol-based workflows and should not be treated as a universal kinase inhibitor or as a direct substitute for a paper-matched protocol.
-
IAM-LC vs LEKC for Pulmonary Permeability
2026-08-29
This 2024 Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for biomimetic drug partitioning and pulmonary permeability assessment. LEKC more closely reflected apparent lung permeability, whereas IAM-LC offered broader compound coverage, simpler implementation, and stronger suitability for high-throughput screening.
-
GRK Control of Biased M1 Receptor Signaling
2026-08-28
A 2025 study used quantitative BRET assays to show that GRK subtype behavior helps determine how the M1 muscarinic receptor engages G proteins and β-arrestin 2. Its analysis of BQCA further indicates that this allosteric modulator can activate M1-associated protein interactions alone and increase acetylcholine sensitivity across both signaling systems.
-
EPZ-6438: Selective EZH2 Inhibitor Guide
2026-08-28
EPZ-6438 is a selective EZH2 inhibitor that blocks SAM-dependent PRC2 methyltransferase activity and reduces H3K27me3. Its nanomolar biochemical activity and activity in SMARCB1-deficient, EZH2-mutant lymphoma, and HPV-associated cancer models support its use in epigenetic cancer research.
-
CLCC1 and Herpesvirus Nuclear Egress: Study Insights
2026-08-27
The reference preprint identifies the host factor CLCC1 as essential for membrane fusion during herpesvirus nuclear egress, distinguishing this poorly understood step from viral capsid envelopment. Its CRISPR-screen and cell-biological findings connect herpesvirus release with nuclear pore complex insertion and suggest an evolutionarily conserved membrane-remodeling mechanism.
-
SMPD4, Ceramide, and Primary Cilia in Brain Development
2026-08-27
The 2024 Development study links SMPD4-dependent ceramide production to primary cilium formation and brain development across mouse and human cellular models. Its rescue experiments provide a mechanistic framework for understanding why SMPD4 variants cause microcephaly, cerebellar hypoplasia, and neural progenitor defects.
-
Tetrandrine: From Ion Channels to Assay Design
2026-08-26
Tetrandrine is a versatile Tetrandrine alkaloid for calcium-channel, inflammation, neuroscience, and cancer biology research. This assay-first guide connects its physicochemical properties with rigorous workflow design and explains how natural-product screening evidence should shape—not overstate—mechanistic conclusions.
-
Atrial Natriuretic Peptide: Rat Workflow Guide
2026-08-26
Build reproducible rat cardiovascular experiments around Atrial Natriuretic Peptide, from solution preparation through renal, vascular, and adipose readouts. The workflow also shows how causal-control logic from a neuroinflammation study can strengthen ANP study design without confusing adiponectin biology with ANP activity.
-
Nuclear cGAS Restricts L1 Retrotransposition
2026-08-25
The reference study identifies a DNA damage-responsive CHK2–cGAS–TRIM41 pathway that limits LINE-1 retrotransposition by destabilizing the L1-encoded ORF2p protein. Its findings expand the role of nuclear cGAS from genome surveillance to post-translational control of mobile genetic elements, with implications for genome integrity, cellular senescence, and tumor biology.
-
BI 2536: Turning PLK1 Biology into Translational Insight
2026-08-25
A mechanistic and strategic guide to using BI 2536 as a selective PLK1 inhibitor for dissecting mitotic checkpoint control, G2/M arrest, apoptosis, and translational cancer research decisions.
-
RG7388: A Mechanistic Guide to MDM2–p53 Research
2026-08-24
RG7388 is a selective MDM2 antagonist for testing p53 pathway activation and cancer cell apoptosis induction in wild-type p53 models. This article connects its pharmacology with new evidence on MDM1, YBX1, and chemoradiotherapy sensitivity to improve assay interpretation and translational study design.
-
PPM-18 for NF-κB and iNOS Research
2026-08-24
PPM-18 enables a focused way to connect NF-κB activation with downstream iNOS expression, nitrite release, and inflammatory cytokines. This workflow-oriented guide covers cell-based inflammation assays, sepsis research considerations, practical controls, and troubleshooting for a chemically defined naphthoquinone derivative.